Autologous dendritic cell-multiple myeloma fusion vaccine (DC/MM fusion vaccine)

The autologous dendritic cell-multiple myeloma (DC/MM) fusion vaccine is a personalized cellular immunotherapy designed to treat multiple myeloma (Avigan et al., 2004, Clinical Cancer Research). It is created by fusing a patient's own dendritic cells, which are professional antigen-presenting cells, with their own malignant plasma cells using polyethylene glycol (Rosenblatt et al., 2011, Blood). This fusion process results in a hybrid cell that displays a comprehensive array of tumor-associated antigens in the context of essential co-stimulatory molecules like MHC class I and II, CD80, and CD86 (Vasir et al., 2005, British Journal of Haematology). When administered back to the patient, typically alongside GM-CSF to enhance recruitment, the vaccine stimulates the expansion of tumor-reactive CD4+ and CD8+ T cells (NIH, ClinicalTrials.gov, NCT02728102). These T cells are then capable of identifying and destroying residual myeloma cells throughout the body. This approach is particularly focused on achieving long-term remission by targeting minimal residual disease following standard treatments like autologous stem cell transplantation.

Other names

DC-myeloma fusionDendritic cell-tumor cell fusionAutologous DC/MM fusion productDC/MM fusion

Induction of a broad, polyclonal T-cell response against multiple myeloma by presenting a comprehensive array of patient-specific tumor-associated antigens within the context of dendritic cell-derived co-stimulatory signals.